LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Home・Lista de Ações・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Fechado

SetorSaúde

25.82 -2.79

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

25.76

Máximo

26.58

Indicadores-chave
By Trading Economics
Rendimento	23M 7.4M
Vendas	18M 99M
EPS	0.06
Margem de lucro	7.468
Funcionários	342
EBITDA	23M 11M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+20.35% upside

Dividendos
By Dow Jones
Próximos Ganhos	25 de fev. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	881M 3.3B
Abertura anterior	28.61
Fecho anterior	25.82

Sentimento de Notícias

By Acuity

50%

155 / 352 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

12.42 / 14.93 Suporte e Resistência

Arcutis Biotherapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

13 de fev. de 2026, 16:32 UTC

Ganhos

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

13 de fev. de 2026, 21:57 UTC

Ganhos

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

13 de fev. de 2026, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

13 de fev. de 2026, 21:20 UTC

Ganhos

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

13 de fev. de 2026, 21:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

13 de fev. de 2026, 20:45 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

13 de fev. de 2026, 20:45 UTC

Conversa de Mercado

Dollar Pares Down Early Losses -- Market Talk

13 de fev. de 2026, 20:39 UTC

Conversa de Mercado

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

13 de fev. de 2026, 20:28 UTC

Conversa de Mercado

Oil Settles Week Lower -- Market Talk

13 de fev. de 2026, 19:51 UTC

Ganhos

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13 de fev. de 2026, 19:32 UTC

Conversa de Mercado

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13 de fev. de 2026, 19:32 UTC

Conversa de Mercado

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13 de fev. de 2026, 19:29 UTC

Ganhos

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

13 de fev. de 2026, 18:18 UTC

Aquisições, Fusões, Aquisições de Empresas

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

13 de fev. de 2026, 17:52 UTC

Ganhos

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

13 de fev. de 2026, 17:16 UTC

Ganhos

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13 de fev. de 2026, 17:10 UTC

Aquisições, Fusões, Aquisições de Empresas

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

13 de fev. de 2026, 16:59 UTC

Ganhos

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

13 de fev. de 2026, 16:39 UTC

Aquisições, Fusões, Aquisições de Empresas

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

13 de fev. de 2026, 16:11 UTC

Ganhos

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

13 de fev. de 2026, 16:07 UTC

Conversa de Mercado

Hungarian Forint Could Rise Further -- Market Talk

13 de fev. de 2026, 15:54 UTC

Ganhos

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

13 de fev. de 2026, 15:26 UTC

Conversa de Mercado

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

13 de fev. de 2026, 15:01 UTC

Ganhos

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

13 de fev. de 2026, 15:00 UTC

Ganhos

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

13 de fev. de 2026, 14:50 UTC

Conversa de Mercado

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

13 de fev. de 2026, 14:44 UTC

Ganhos

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

13 de fev. de 2026, 14:22 UTC

Conversa de Mercado

Ganhos

Global Energy Roundup: Market Talk

13 de fev. de 2026, 14:21 UTC

Conversa de Mercado

Ganhos

TC Energy's Broadly Anticipated Results Expected To Have Neutral Response -- Market Talk

13 de fev. de 2026, 14:13 UTC

Conversa de Mercado

U.S. Natural Gas Futures Move Lower -- Market Talk

Comparação entre Pares

Variação de preço

Arcutis Biotherapeutics Inc Previsão

Preço-alvo

By TipRanks

20.35% parte superior

Previsão para 12 meses

Média 32 USD 20.35%

Máximo 37 USD

Mínimo 30 USD

Com base em 7 analistas de Wall Street que oferecem metas de preço de 12 meses para Arcutis Biotherapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

7 ratings

Comprar

Manter

Vender

Com base em 7 analistas que deram avaliações de ações para Arcutis Biotherapeutics Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

12.42 / 14.93Suporte e Resistência

Recent bearish events outweigh bullish events.

There is one bullish event.

Sentimento

By Acuity

155 / 352 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.